Vadim Baram, MD
Psychiatry · Saint Louis, MONPI 1124007380
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,577,448 of the $1,863,371 with a category attached, or 84.7%. 46 manufacturers reported payments, led by Alkermes, Inc. at 26.8% of the total. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 5,365 payments — averaging $347.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$499K
- Neurocrine Biosciences, Inc.$320K
- Vanda Pharmaceuticals Inc.$290K
- Teva Pharmaceuticals USA, Inc.$247K
- Avanir Pharmaceuticals, Inc.$189K
- E.r. Squibb & Sons, L.L.C.$83K
- plus $235K from 40 others
Across 4 payments — averaging $1487.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$3K
- Alkermes, Inc.$3K
What the payments were for
- Consulting fees$48,6093%
- Speaking & faculty fees$1,577,44885%
- Travel & lodging$142,0058%
- Food & beverage$94,7475%
- Education$5620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,863,371 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 194 | $1,588,962 |
| AristadaAripiprazole Lauroxil | 347 | $1,082,071 |
| AustedoDeutetrabenazine | 179 | $935,767 |
| Austedo XrDeutetrabenazine | 124 | $915,497 |
| LybalviOlanzapine/Samidorphan Malate | 406 | $614,490 |
| Invega SustennaPaliperidone Palmitate | 75 | $230,198 |
| NuplazidPimavanserin Tartrate | 47 | $213,322 |
| FanaptIloperidone | 89 | $207,638 |
| WakixPitolisant Hcl | 13 | $143,139 |
| NuedextaDextromethorphan Hbr/Quinidine | 91 | $130,414 |
| TrintellixVortioxetine Hydrobromide | 244 | $127,663 |
| Invega TrinzaPaliperidone Palmitate | 12 | $107,446 |
| UzedyRisperidone | 34 | $106,162 |
| CaplytaLumateperone Tosylate | 63 | $99,662 |
| SpravatoEsketamine Hcl | 77 | $89,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $247,056 | $1,957,426337 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $499,376 | $1,726,851771 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $320,306 | $1,588,962194 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Spravato | $9,790 | $427,130164 claims |
| Acadia Pharmaceuticals IncNuplazid | $52,006 | $213,32247 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $289,657 | $207,63889 claims |
| Harmony Biosciences LLCWakix | $1,995 | $143,13913 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $189,070 | $130,41491 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $8,701 | $127,663244 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $43,567 | $99,66263 claims |
| Bausch Health US, LLCAplenzin | $1,422 | $84,49719 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $44 | $36,489514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
- Eric LenzeSaint Louis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.